# Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

> **NCT05726084** · PHASE2,PHASE3 · UNKNOWN · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 16304 (estimated)

## Conditions studied

- COVID-19
- Coronavirus Infections
- Respiratory Tract Infections
- COVID-19 Respiratory Infection

## Interventions

- **BIOLOGICAL:** Subunit recombinant vaccine for the prevention of coronavirus infection
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05726084
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-24
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 16304 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726084, "Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05726084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*